ACR Convergence 2026: key results and trends

BEL/RTX was superior with respect to the primary endpoint of treatment failure (HR 0.39 [0.19-0.77], p=0.005), with treatment failure occurring in 12 patients in the BEL/RTX group versus 25 patients in the SoC group.

SSGJ-613 significantly delayed time to first new flare, and the risk of new flares was reduced by 77% compared with CB (HR: 0.23, 95% CI 0.17 to 0.32 ; P < 0.0001) within 12 weeks.

EGPA-related events occurred in 29.4% and 63.3% of patients, respectively (adjusted hazard ratio, 0.39; 95% CI, 0.21-0.72; P=0.003), mainly owing to fewer asthma and ENT exacerbations.

For major morbidity/mortality events, sotatercept reduced the risk of a first event versus placebo (HR 0.39 [95% CI: 0.19-0.83]; P=0.006), with 12 sotatercept-treated versus 25 placebo-treated participants having ≥1 event.

Importantly, nerandomilast also reduced the risk of disease progression (key secondary endpoint) by 84% with the 9 mg dose (hazard ratio [HR]: 0.16; 95% CI 0.02 to 0.98) and 94% (HR: 0.06; 95% CI < 0.01 to 0.61) with the 18 mg dose.

Time to first attainment favored anifrolumab for DORIS (HR 3.18, 95% CI, 1.42 to 8.08) and LLDAS (HR 2.63, 95% CI, 1.77 to 3.99).

The proportion of patients with serious adverse events (SAEs) was 3.9% in the girocitinib group and 6.6% in the tofacitinib group; treatment-related SAEs occurred in 1.3% and 2.6% of patients in girocitinib and tofacitinib groups, respectively.

Over the 28-week treatment period, the incidences of treatment-emergent adverse events (TEAEs) were similar between groups (82.3% vs 83.9%), as were treatment-related TEAEs (54.2% vs 56.8%) and serious TEAEs (2.4% vs 3.6%).

At Week 24, the most common AEs with envudeucitinib were headache (10.9%), nasopharyngitis (10.3%), acne (6.7%), and upper respiratory tract infection (6.4%).

At W68, mean changes from baseline in WOMAC Pain subscale scores were -4.48 (RETA 9 mg), -4.41 (RETA 12 mg) and -2.43 (PBO); mean percent changes in BW were -26.4% (RETA 9 mg), -28.7% (RETA 12 mg) and -2.1% (PBO); p< 0.001 vs PBO for all.

At W48, both dazodalibep regimens significantly improved ESSDAI vs PBO: LS mean change was −5.6 with 1500 mg Q4W (difference vs PBO, −1.8; adjusted p< 0.001), −5.2 with 3000 mg Q12W (difference vs PBO, −1.4; adjusted p=0.010), and −3.8 with PBO.

Related TEAEs were also comparable between DRL_AB (9.6%) and RMP (13.2%) over the entire study period.